The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, explores chemotherapy-free treatment regimes for light chain (AL) amyloidosis. Specifically discussed are daratumumab and isatuximab, both CD38 monoclonal antibodies being investigated for the treatment of AL amyloidosis, as well as venetoclax, a BCL-2 inhibitor in amyloidosis patients with an 11;14 translocation. Dr Lentzsch also elaborates on emerging therapies that target AL amyloid deposits, including the results of the Phase III VITAL study (NCT02312206) evaluating birtamimab (NEOD001) in patients with AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
